Devon Carr, MD
Internal Medicine · Athens, GANPI 1558704999
Payments from drug & device makers
Across 235 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$709
- Amgen$385
- GSK$375
- Lilly USA, LLC$311
- AstraZeneca$258
- Novo Nordisk$198
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,703100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $709 |
| Amgen | 24 | $385 |
| GSK | 26 | $375 |
| Lilly USA, LLC | 20 | $311 |
| AstraZeneca | 16 | $258 |
| Novo Nordisk | 12 | $198 |
| Amarin Pharma, Inc. | 7 | $122 |
| Esperion Therapeutics, Inc. | 5 | $106 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| Mylan Specialty L.p. | 4 | $99 |
| Pfizer | 6 | $96 |
| Exact Sciences | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Supernus Pharmaceuticals, Inc. | 5 | $83 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Dexcom, Inc. | 3 | $64 |
| Merck | 4 | $56 |
| Philips North America LLC | 3 | $50 |
| Paratek Pharmaceuticals, Inc. | 3 | $49 |
| Abbott | 2 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $37 |
| Shire North American Group Inc | 2 | $32 |
| Lundbeck LLC | 1 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Saluda Medical Americas, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Optos, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Linus Health, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $12 |
How this compares
$3,717 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 118 | $142,713 |
| OzempicSemaglutide | 77 | $91,083 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $82,581 |
| EliquisApixaban | 65 | $78,882 |
| FarxigaDapagliflozin Propanediol | 50 | $66,564 |
| RybelsusSemaglutide | 22 | $39,441 |
| JardianceEmpagliflozin | 32 | $35,930 |
| XareltoRivaroxaban | 24 | $32,312 |
| BelsomraSuvorexant | 68 | $31,968 |
| VraylarCariprazine Hcl | 21 | $29,664 |
| Repatha SureclickEvolocumab | 22 | $28,023 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $27,332 |
| JanuviaSitagliptin Phosphate | 20 | $27,291 |
| LinzessLinaclotide | 16 | $21,430 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $19,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $311 | $161,649132 claims |
| Novo NordiskOzempic, Rybelsus | $198 | $130,52499 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $258 | $93,89675 claims |
| GSKTrelegy Ellipta | $375 | $82,58151 claims |
| PfizerEliquis | $96 | $78,88265 claims |
| MerckBelsomra, Januvia, Dulera | $56 | $63,400100 claims |
| AbbVieVraylar, Linzess | $709 | $51,09437 claims |
| Boehringer IngelheimJardiance | $13 | $35,93032 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $99 | $19,53615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Athens
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.